SynthesisWorld journal of surgical oncology2023

Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

What the trial testedas reported · 2,294 people · 2023

Not counted

3.3×2× to 5.3×

Bigger than 9 in 10 for adverse events & safety

As reported

OR 3.28, 95% CI 2.01–5.35

the abstract, start to end

… pathological response on TRG (OR: 3.28, CI: 2.01-5.35, I CONCLUSIONS: …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 3.282.01–5.35

MetforminAdverse events & safety

1 / 3

2023

2024

2025

2026

this papercites it